Drug intelligence / Profile preview

quinolixin

Development stage: Unknown
Lead developer: Shanghai Institute of Materia Medica
Modality: Small Molecules
Administration: Oral

Overview

Quinolixin is a novel small molecule alpha-1A adrenergic receptor antagonist developed by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences. It is specifically designed for the treatment of benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS). By selectively inhibiting the alpha-1A receptors located in the smooth muscle of the prostate and bladder neck, quinolixin promotes muscle relaxation, which improves urinary flow and reduces obstructive symptoms. As of 2024, the drug is in Phase 2 clinical development in China (e.g., trial CTR20241404), where its efficacy, safety, and pharmacokinetics are being evaluated in comparison to silodosin, a highly selective alpha-1A blocker.

Other names: 喹诺利嗪

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on quinolixin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on quinolixin.

Explore the full profile